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Imaging appearance of cyst-like changes is most frequently described in primary neuroendocrine lesions, especially
pancreatic NETs.
The imaging finding of a pseudocystic lesion of the liver puts in differential diagnosis many pathologies such as
infectious diseases, simple biliary cysts up to biliary cystadenomas and eventually to primary or metastatic malignancies.
Primary or metastatic hepatic malignancies with pseudocystic aspects are rare, and a pseudocystic aspect is reported
only after neo-adjuvant treatment.
Liver metastasis of untreated neuroendocrine tumors are usually solid and, to our knowledge, only two cases of
neuroendocrine cystic hepatic metastases of ileal atypical carcinoids have been reported so far.
We present a case of a 67 years old man with synchronous finding of an untreated hepatic pseudocystic lesion and an
ileal mass histologically diagnosed as a well differentiated (G1) neuroendocrine tumor.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1443883503102967.
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Gastro-entero-pancreatic neuroendocrine tumors (NETs) are
uncommon, accounting for around 2% of all gastrointes-
tinal tumors [1-3], and are characterized by disparate clin-
ical and pathological features. Their incidence has been
on the rise over the last two decades; this, along with an
overall good prognostic expectancy, explains the relatively
high prevalence estimate of 35/100.000 [4].
This family of heterogeneous neoplasms is thought to
derive from the gastrointestinal diffuse endocrine sys-
tem, and includes functioning tumors, which secrete a
variety of peptide hormones with the resulting clinical
syndromes, and non-functioning tumors. The lattest are
often metastatic at the time of diagnosis. Even if the ma-
jority of NETs are well-differentiated, low-grade tumors,
others may show an aggressive, frankly malignant behavior.* Correspondence: alessandro.delgobbo@unimi.it
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reproduction in any medium, provided the orHistopathological grading of these lesions has been recently
reviewed: the 2010 WHO classification acknowledges and
emphasizes the malignant potential of neuroendocrine
neoplasms [5]. According to this classification, based on
the tumor’s proliferative features (mitotic count and Ki67
proliferation index) three grades are identified, and they
are illustrated in Table 1.
Ki67 labeling index cut off of 3% allows the division of
NETs in well-differentiated and moderately differentiated
and it predicts metatasis or recurrence [6].
Synaptophysin and Chromogranin A are the most useful
markers to differentiate NETs from non-endocrine poorly
differentiated adenocarcinoma [7].
Small bowel is the most common site of presentation of
gastrointestinal NETs (44.7%), followed by rectum (19.6%),
colon (17%), appendix (16.7%), pancreas (12.1%) and stom-
ach (8.9%) [8].
The most frequent site of metastases of gastrointes-
tinal NETs, apart from regional lymphnodes, is the liver:
hepatic metastases are found at the time of diagnosis in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Histopathological characteristics of neuroendocrine carcinomas of the small intestine [5]
Histotype Mitoses Ki67 index Nuclear atypia Necrosis Immunoreactivity
Well differentiated (G1- carcinoids) < 2/10 HPF < 2% Absent Absent Synaptophysin (+)
Chromogranin A (+)
Moderately differentiated (G2) 2–20/10 HPF 3-20% May be present May be present Synaptophysin (+)
Chromogranin A (+)
Poorly differentiated (G3 - neuroendocrine carcinoma) > 20/10 HPF > 20% Usually present Usually present Synaptophysin (+)
Chromogranin A (−/+)
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more, 59–80% of patients with pancreatic non-insulinoma
tumors bear synchronous liver metastases [10]. In a mi-
nority (5–14%) of patients with NET liver metastases, the
primary tumor can’t be identified.
An aggressive surgical management of neuroendocrine
hepatic metastases has been demonstrated to improve
5-years survival rates [11], hence the importance of an
accurate histological diagnosis.
Liver metastases are usually solid with a dense capillary
network; thereby, computerized tomography (CT) and
magnetic resonance (MR) scans reveal hypervascularization
with arterial phase enhancement.
A small minority of hepatic NET metastases have a
cystic appearance at standard cross-sectional scans, and
may be mistaken for benign lesions. Cystic changes, due
to central tumor necrosis, are described in NET hepatic
metastases as a result of chemotherapic treatment.
A primary cystic appearance is exceedingly rare in un-
treated cases. At the best of our knowledge, only two
other cases of cystic hepatic metastases of untreated ileal
NETs have been reported [12,13].
We present a case of a 67 years old man with syn-
chronous finding of a hepatic pseudocystic lesion and an
ileal mass, histologically diagnosed as a well differenti-
ated (G1) NET.Case presentation
Clinical presentation
A 67 years old man was referred to our attention for an
incidental finding (during routine abdominal ultrasonog-
raphy) of four hepatic lesions. He had a history of hyper-
tension, ischemic cardiomyopathy, chronic obstructive
pulmonary disease and prostatic nodular hyperplasia.Figure 1 Computed tomography portal contrast phase image
showing the presence of three slightly hypodense nodular
lesions (arrows), the larger sited in the medial wall of a large
cyst in segment VII.Diagnostics
Ultrasonography showed that three lesions, in segments
III and VII, were solid, less than 2 cm in diameter; the
fourth one, in segment VII, was a 9 cm multilocular cyst
with mixed echostructure (hyperechogenic with fluid
content).
An abdominal contrast-enhanced CT scan (Figure 1)
confirmed all the four lesions, and revealed three furthersubcentimetric nodules, in hepatic segments II, III and
VII.
The cyst showed a portal-phase enhancement in walls
and inner septa. Moreover, a 3 cm thickening of terminal
ileum wall, and an enlarged (cm 1.5) mesenteric lymphnode
were highlighted.
A pan-colonoscopy confirmed the ileo-caecal mass. Histo-
logical examination of the endoscopic biopsy specimens was
consistent with a well differentiated (G1) NET. Immuno-
staining for both Synaptophysin and Chromogranin A
turned out positive. Afterwards, a fine-needle biopsy of a III
segment nodular lesion was performed: histological diagno-
sis was of well-differentiated (G1) NET hepatic metastasis.
Plasma Chromogranin A levels were evaluated, and
turned out raised (1096 U/I; r.v. <33), as well as
5-indolacetic acid urinary excretion (58.9 mg/g creatin-
ine; r.v. 2.0-10.0). Clinical staging was concluded with a
111In-pentetreotide somatostatin receptor scintigraphy,
which displayed intestinal and plurifocal hepatic hyper-
captation (Figure 2).
Figure 2 111Indium-pentetreotide scintigraphy showing
multiple intrahepatic hypercaptations; the more posterior of
them (arrow) is near to a large cyst sited in segment VII.
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The patient underwent a synchronous right hemicolecto-
my, left hepatic lobectomy, VII segment resection and
cholecystectomy with concurrent radiofrequency ablation
of the subcentimetric hepatic nodules. Postoperative
course was regular, and a medical regimen of somatostatin
analogs (SSAs) was started.
Gross examination and histology
Gross examination of the resected specimens revealed a
2.5 cm peduncolated mass in the terminal ileum, a
14 cm thick-wall pseudocystic lesion with bloody con-
tent in VII hepatic segment (Figure 3), and several smallFigure 3 Gross view of the hepatic pseudocystic metastasis
specimen, showing the peripheral solid wall, the bloody
content and with the surrounding normal hepatic parenchyma.(1.4 cm the largest), whitish nodules in the left hepatic
lobe. The gallbladder contained yellowish gallstones.
Microscopically, the ileal tumor was composed of roun-
ded nests of closely packed, monomorphous cells lacking
atypia, and with a peripheral-palisading pattern of growth.
The tumor exhibited infiltration of perivisceral adipose
tissue, along with two mesenteric nodal metastases
(Figure 4A). The pseudocystic hepatic lesion showed
two different components: a peripheral thick wall, which
resembled the ileal tumor, and a blood-filled core, with
thin fibrous septa and floating neoplastic cells (Figure 4B).
All the other hepatic nodules were consistent with NET
metastases. The gallbladder and all the surgical margins
were free of disease.
Mitotic count was lower than 2/10 HPF, and Ki67 prolif-
erative index (Ventana, clone 30–9) turned out 1% in both
primary and metastatic lesions. All the described lesions
showed a positive reaction to Synaptophysin (Ventana,
clone MRQ-40) and Chromogranin A (Ventana, clone
LK2H10).
Moreover, immunohistochemical stainings for Insulin
(DAKO, clone IN-05), Glucagon (DAKO, clone A56501),
VIP (Sigma Aldrich, polyclonal) and Serotonin (DAKO,
clone 5HT-H209) were performed: only Serotonin stained
weakly positive in the ileal mass and in the cystic lesion
(Figure 4C and 4D).
According to the 2010 World Health Organization
(WHO) Classification of Tumors of the Digestive System
[5], the final diagnosis was of well differentiated (G1)
neuroendocrine tumor of the ileum, with hepatic and
nodal metastases. Pathological stage, in agreement with
the TNM classification of malignant tumors (VII edition,
2009) was pT3, N1, M1. Clinical stage was IV.
Post operative outcome and follow-up
The patient was discharged without complications after
fifteen days of recovery. Nine months later he is in good
health, with no evidence of residual disease and under a
medical regimen of long-acting SSAs.
Discussion
Hepatic neoplasms with cystic features are rare [14].
The imaging finding of a pseudocystic lesion of the
liver, in absence of clinical symptoms, implies several
differential diagnoses, ranging from infectious diseases
such as echinococcal cysts [15], benign lesions as simple
biliary cysts and biliary cystadenomas, up to primary or
metastatic malignancies.
Two cases of pseudocystic GEP/NETs liver metastases
[12,13] and two primary hepatic pseudocystic NETs [16,17]
have been described.
However, this is the first case of a G1 NET that provoked
pseudocystic hepatic metastasis. Hepatic pseudocystic sec-
Figure 4 Blood-filled core and delicate septa. (A) Microscopic view of the primary ileal tumor, composed of rounded nests of closely packed,
monomorphous cells (EE, 10×). (B) The same architectural pattern of the hepatic metastasis, with the central, blood-filled core of blood and delicate septa
of tumoral cells (EE; 10x). (C-D) Granular, cytoplasmic immunostaining for serotonin in both primary and metastatic tumors (20×).
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oma [1], spinal haemangiopericytoma [2] and nasopharyn-
geal carcinoma [3].
Neuroendocrine tumors can undergo pseudocystic me-
tastases in different sites: a cerebral cystic metastasis of
neuroendocrine carcinoma, with unknown primary
tumor, has been reported [18].
Cystic changes are often reported in liver malignancies
after a neo-adjuvant treatment. This is thought to be
due to therapy-induced tumor necrosis [14].
A pseudocystic appearance with a peculiar peripheral
contrast enhancement are described in pancreatic NETs
[15] and in a case of a case of primary micro-neuroendocrine
tumor arising in a horseshoe kidney [19].
Primary cystic NETs display a less frequent tendency
to undergo nodal and hepatic spread when compared to
solid counterparts.
We observed an aggressive behaviour, with multiple
hepatic and nodal metastases in a well differentiated (G1)
ileal NET at the time of diagnosis.
In our case, once the neuroendocrine nature of the pri-
mary ileal mass was histologically confirmed, the 111In-
pentetreotide somatostatin receptor scintigraphy revealed
the same capitation pattern in the hepatic cyst, suggesting
its secondary nature. Taking account on these acknowl-
edgements, a complete resection of the cyst was performed.Neo-adjuvant chemotherapy was not performed, despite
the advanced clinical stage [20].
Both macroscopic and microscopic examination showed
that the pseudocystic appearance of this metastasis was
not due to the central necrosis, but to intratumoral
haemorrhage.
All the described findings were incidental, and patient
did not complain for pain, flushing, diarrhea or other
symptoms related to a ‘’hypersecretion syndrome”. For
this reason, the hepatic pseudocyst could have been
misdiagnosed, unless an ileal mass was identificated and
raised the suspicion for a metastatic NET.
A complete resection of NET hepatic metastases leads
to an improved prognostic outcome: 5-years overall sur-
vival rates higher than 70% [21] are reported, despite re-
currences develop in up to 80% of patients [22]. Thus,
the rationale to remove NET liver metastases, once tech-
nically feasible, is established. In order to either obtain
an accurate pre-treatment assessment and plan an ad-
equate surgical strategy, it is crucial to differentiate liver
NET metastases from other primary or secondary hep-
atic malignancies (that may not take advantage of the
similar prognostic improvements), as well as from be-
nign lesions. For these reasons, we recommend to keep
in consideration unusual NET presentations, such as the
described one.
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